News NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
Market Access Women's health: Predictions for 2026 A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.
News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.
News Poll paints picture of menopause discrimination at work A survey of women across six countries has found more than a third have experienced some kind of negative impact in the workplace due to menopause.
News Gedeon Richter brings HRT option back to the UK market After a 17-year absence, a dydrogesterone-only hormone replacement therapy (HRT) formulation is available again in the UK market.
R&D Medicine’s blind spot: How clinical trials are failing women From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.